Loading
BD
Beryl Drugs Stock: price and insider trades · India
IN·Mcap ₹128.2M
1 insider bought €1,619 of shares over the last 90 days, the latest by Sudhir Sethi, filed 24 Aug 2026.
Beryl Drugs: what insiders have been doing
Every trade that managers of Beryl Drugs disclose to SEBI (PIT + SAST) is tracked on this page. In the past year (18 October 2025 to 18 October 2026), 12 filings came from 2 insiders.
The flow runs one way only: 2 insiders bought (12 purchases totalling €3,042) and nobody sold on the market. No amount is published for 7 filings, which the totals therefore leave out. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. On the buying side, the filings list 1 major shareholder and 1 senior executive among the declarants. The largest single trade was a purchase of €1,021 by Sudhir Sethi, published on 9 June 2026, equal to 0.088% of the market capitalisation.
The last insider purchase was made public on 24 August 2026, 55 days ago. Most trades are made public on the day they happen. Until a filing is published, the market cannot know about the trade.
With 12 filings in twelve months, the company is more active than the median of 4 filings across the 1,985 companies we follow on the same exchange. Our records for Beryl Drugs go back to 2026, with 12 purchases and no sales on the open market in total.
Every figure here comes from the filings published by SEBI (PIT + SAST) and describes the past, not future prices; it is not investment advice.
Insider Decl.
12
Thresholds
n/a
Buy Volume
€3,042
12 ops. · all time
Sell Volume
n/a
n/a
Who traded when
BuySaleSudhir Sethi12 buys
Since the insiders bought
- +1.3%Entry ₹25.48 · Close at T+30 ₹25.80
- +3.6%Entry ₹22.20 · Close at T+30 ₹22.99
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 11,623 of 23,476 companies
51.9
score / 100
Value57
Quality47
FCF yld-1.4%
Earn yld3.5%
EV/EBITDA6.0x
ROE4.4%
Gross mgn29%
Net mgn2.3%
Debt/EBITDA1.0x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2026FY ended March 2026 · cache
₹25.27
Analyst consensus
Income statement
Revenue₹186.8M
Gross profit₹54.2M29% margin
EBITDA₹24.1M13% margin
Net income₹4.2M2.9% margin
Valuation
PER (trailing)15.7x
P/Book1.3x
Beta0.16
Balance sheet & cash
Market cap₹128.2M
Total debt₹24.4M
Free Cash Flow-₹1.7M
Debt / Equity25%
Profitability & ownership
ROE4.4%
ROA3.8%
% insiders40.5%
% institutions0.0%
Last declaration on 24 August 2026
Declarations12 total
3,000 shares-MarketSEBI:76174dd04aab1be261ec2cc56ab33189988c6302
Canonical exit: 22 Nov 2026 (T+90)
4,809 shares-MarketSEBI:fe369378dd180e18d582aee36ecd381ebe55dccc
Canonical exit: 22 Nov 2026 (T+90)
4,809 shares@ ₹23.000.095% mcap32.7% of flowEquityMarket PurchaseSEBI:6b2d3b91da8600f142e36574857ec2540e736764
Canonical exit: 17 Nov 2026 (T+90)
3,000 shares@ ₹23.000.059% mcap20.5% of flowEquityMarket PurchaseSEBI:b12862567d2a23cf34966e18c726b7e70779015d
Canonical exit: 16 Nov 2026 (T+90)
6,950 shares-MarketSEBI:ce1bfd3c3db694d98810fe5782b323d924a4272a
Canonical exit: 14 Oct 2026 (T+90)
3,482 shares-MarketSEBI:f08604d79c000fed86c0ad77be27ba8d8438873e
Canonical exit: 15 Sept 2026 (T+90)
4,682 shares-MarketSEBI:530e5b8895b90e69ad5e65876b0fdf57080418cf
Canonical exit: 15 Sept 2026 (T+90)
30 shares-MarketSEBI:eb42d37f8d98b4c7a7399a34cd244e3b840e8218
Canonical exit: 15 Sept 2026 (T+90)
1,992 shares-MarketSEBI:40b7fbdb8d06de15ddf58d7b74849c3e97a314df
Canonical exit: 15 Sept 2026 (T+90)
30 shares@ ₹23.500.0006% mcap0.2% of flowEquity SharesMarket PurchaseSEBI:595b5ff051ac5a14d4d7336b9c8cc0750a5ba482
Canonical exit: 10 Sept 2026 (T+90)
4,682 shares@ ₹24.000.088% mcap33.6% of flowEquity SharesMarket PurchaseSEBI:98926893d7a2c99c398ecb3a859d9ab11f7762d3
Canonical exit: 7 Sept 2026 (T+90)
1,992 shares@ ₹21.9013.0% of flowEquity SharesMarket PurchaseSEBI:871849245ba4ff15416a55af3e35553ca46d23fa
Canonical exit: 5 Sept 2026 (T+90)
12 of 12 declarations
About Beryl Drugs
Beryl Drugs is a pharmaceutical company that offers a range of medical products. It is listed on the XBOM.
